Following its own evaluation of the safety and toxicology of AlaskOmega 50% and 70% omega-7 concentrates, the U.S. Food and Drug Administration does not dispute the GRAS status of the ingredient.
Photo © Shutterstock.com/AlexLMX
Organic Technologies (Coshocton, OH), maker of AlaskOmega omega-3 and omega-7 concentrates, received a “no questions” letter from FDA regarding the self-affirmed GRAS (generally recognized as safe) status of AlaskOmega 50% and 70% omega-7 concentrates. The ingredient became self-affirmed GRAS after a comprehensive review of the safety, toxicology and proposed usage by an independent scientific panel of experts who unanimously agreed that AlaskOmega omega-7 concentrates are safe for use in foods and beverages. FDA’s “no questions” letter indicates that following its own independent evaluation of the safety and toxicological data, the agency does not dispute the GRAS claim.
Omega-7, or palmitoleic acid (C16: n1), is a monosaturated fat that has a wide range of potential health benefits including heart health, inflammation, metabolic health, satiety, and anti-aging for skin, hair, and nails. GRAS status means AlaskOmega 50% and 70% omega-7 concentrates can be incorporated into food and beverage products without regulatory barriers.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.